Clinical trials: in Russia
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor…
- Trial name
- SELECT-1 (NCT01933932)
- Testing
- Selumetinib, Docetaxel, Pegylated G-CSF
- Where
- 197 sites in United States, Argentina and 24 more
- Volunteers
- 510 people
- Sponsor
- AstraZeneca
Rare Diseases, Neuromyelitis Optica Spectrum Disorder (NMOSD)
Epidemiological Study of Treatment Approaches on AQP4-IgG Positive NMOSD in Russia
This is a multi-centre, retrospective-prospective, single-arm, non-interventional (observational) cohort study with secondary data collection within real-world settings of participants with AQP4-IgG positive NMOSD.
- Trial name
- NCT07247292
- Where
- Russia
- Volunteers
- 3 people
- Sponsor
- AstraZeneca
Efficacy, Self, Fatigue; Muscle, Heart
Neuromodulation of the Autonomic Nervous System in Athletes
There are few studies in the literature that have evaluated the effects of using percutaneous stimulation of the auricular branch of the vagus nerve for sports purposes (to accelerate recovery after physical exertion).
- Conditions
- Efficacy, Self, Fatigue; Muscle, Heart, Fatigue, Mental, Fatigue; Combat
- Trial name
- NANSA (NCT06281795)
- Testing
- tVNS
- Where
- Russia
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Bakulev Scientific Center of Cardiovascular Surgery
Vagus Nerve Stimulation, Acute Coronary Syndrome
Auricular Vagus Stimulation and STEMI
At the moment, the invasive strategy for the infarct-associated coronary artery in patients with ST-segment elevation myocardial infarction (STEMI) necessary to save the myocardium and reduce the size of the necrosis zone remains…
- Conditions
- Vagus Nerve Stimulation, Acute Coronary Syndrome, Ischemia Reperfusion Injury
- Trial name
- NCT05992259
- Testing
- TENS
- Where
- Russia
- Volunteers
- 110 people
- Sponsor
- Bakulev Scientific Center of Cardiovascular Surgery
Stroke, Acute Cerebrovascular Accident
Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium
Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times.
- Conditions
- Stroke, Acute Cerebrovascular Accident, Transient Ischemic Attack, Death
- Trial name
- NCT06253000
- Testing
- Cryoablation, Radiofrequency ablation
- Where
- Russia
- Volunteers
- 158 people
- Sponsor
- Bakulev Scientific Center of Cardiovascular Surgery
Vagus Nerve Stimulation, Heart Rate Variability
Auricular Vagus Stimulation and Heart Rate Variability
Transcutaneous electrical stimulation of the auricular vagus nerve (TENS) is a promising method of neuromodulation of the autonomic nervous system in patients with various pathologies.
- Trial name
- NCT05680337
- Testing
- TENS
- Where
- 3 sites in Russia
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Bakulev Scientific Center of Cardiovascular Surgery
Carcinoma, Non-Small-Cell Lung
Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation
This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II…
- Trial name
- PACIFIC-4 (NCT03833154)
- Testing
- Durvalumab, (Osimertinib cohort, single-arm, open-label separate cohort)
- Where
- 209 sites in United States, Australia and 18 more
- Volunteers
- 724 people
- Sponsor
- AstraZeneca
Atherosclerosis, Atheroscleroses, Coronary
SIALIDASE INHIBITION AS ANTIATHEROSCLEROTIC THERAPY
The aim of this double-blind, randomized, placebo-controlled, multicenter study is to evaluate the pathogenetic effects of the dietary supplement "Tertinat" on a fundamental mechanism of atherosclerosis development: its ability…
- Conditions
- Atherosclerosis, Atheroscleroses, Coronary, Carotid Atherosclerosis
- Trial name
- SIAT (NCT06590012)
- Testing
- Tertinat
- Where
- 10 sites in Russia
- Volunteers
- 1,228 people
- Sponsor
- Institute for Atherosclerosis Research, Russia
Asthma
Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)
Primary Objective: The primary objective of the study is to characterize patients initiating DUPIXENT for asthma in a real-world setting, with respect to their medical history, including asthma history and asthma treatment…
- Trial name
- REVEAL (NCT04550962)
- Testing
- Dupilumab SAR231893
- Where
- 41 sites in Argentina, Chile and 10 more
- Volunteers
- 376 people
- Sponsor
- Sanofi
Asthma
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment…
- Trial name
- NCT01867125
- Testing
- Lebrikizumab
- Where
- 181 sites in United States, Argentina and 24 more
- Volunteers
- 1,081 people
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis
This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo.
- Trial name
- NCT04090411
- Testing
- Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W
- Where
- 166 sites in United States, Australia and 21 more
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Myelodysplastic Syndromes
Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
The purpose of this study is to evaluate the efficacy and safety of imetelstat sodium in transfusion-dependent participants with low or intermediate-1 risk myelodysplastic syndrome (MDS) that is relapsed/refractory to…
- Trial name
- NCT02598661
- Testing
- Imetelstat Sodium
- Where
- 126 sites in United States, Belgium and 15 more
- Volunteers
- 289 people
- Sponsor
- Geron Corporation
Coronary Artery Disease (CAD), Chronic Coronary Syndrome
"Expert IVUS-Eye" vs. IVUS-guided Left Main Bifurcation PCI
This is a prospective, randomized, controlled trial comparing two strategies for optimizing stent implantation during bifurcation stenting of the left main coronary artery (LM): an intravascular ultrasound (IVUS)-guided approach…
- Conditions
- Coronary Artery Disease (CAD), Chronic Coronary Syndrome, Left Main Coronary Artery Disease, Coronary Bifurcation Lesion
- Trial name
- EYE-IVUS LM (NCT07711106)
- Testing
- IVUS-Guided LM PCI, "Trained Eye" (Angiography-Guided) LM PCI
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health
Asthma
A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to Moderate Asthma
This Phase III, randomized, double-blind, placebo-controlled, multicenter study will assess the efficacy and safety of lebrikizumab in adult patients with mild to moderate asthma treated with short-acting beta-agonist (SABA)…
- Trial name
- NCT02104674
- Testing
- Lebrikizumab, Montelukast
- Where
- 82 sites in United States, Brazil and 9 more
- Volunteers
- 313 people
- Sponsor
- Hoffmann-La Roche
Chronic Lymphocytic Leukemia
ALICIA (Acalabrutinib in CLL Therapy)
This is a multicenter non-interventional observational study conducted with a single hand arm to collect real-world data. In this study, commercially available acalabrutinib will be used as prescribed treatment for CLL as per the…
- Trial name
- ALICIA (NCT04746950)
- Where
- 15 sites in Russia
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
High Grade Gliomas
Preoperative Proton Irradiation for High-grade Brain Gliomas.
The goal of this clinical trial is to learn if preopearative proton therapy (PPT) is tolerable in patients with High-grade brain gliomas.
- Trial name
- PPrestige (NCT07710040)
- Testing
- Preoperative irradiation
- Where
- Russia
- Volunteers
- 9 people
- Sponsor
- National Medical Research Radiological Centre of the Ministry of Health of Russia
Small Cell Lung Carcinoma Extensive Disease
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of combining durvalumab ± tremelimumab with platinum based chemotherapy (EP) followed by durvalumab ± tremelimumab…
- Trial name
- CASPIAN (NCT03043872)
- Testing
- Durvalumab, Tremelimumab, Carboplatin
- Where
- 207 sites in United States, Argentina and 21 more
- Volunteers
- 987 people
- Sponsor
- AstraZeneca
Bladder Cancer
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current…
- Trial name
- KEYNOTE-B15 (NCT04700124)
- Testing
- Pembrolizumab, Enfortumab vedotin (EV), RC + PLND
- Where
- 188 sites in United States, Argentina and 27 more
- Volunteers
- 808 people
- Sponsor
- Merck Sharp & Dohme LLC
Myeloproliferative Disorders, Myelofibrosis
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
The purpose of this Phase 3 study is to evaluate the efficacy and safety of Luspatercept compared with placebo in subjects with myeloproliferative neoplasm (MPN)-associated Myelofibrosis (MF) and anemia on concomitant Janus…
- Conditions
- Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
- Trial name
- INDEPENDENCE (NCT04717414)
- Testing
- ACE-536
- Where
- 185 sites in United States, Argentina and 24 more
- Volunteers
- 313 people
- Sponsor
- Celgene
Sepsis
Extracorporeal cfDNA Removal in Septic Shock Patients With Elevated DNA Levels
Sepsis continues to be a major global health concern, characterized by high morbidity and mortality rates. As a clinical syndrome characterized by a dysregulated systemic response to infection, its progression toward…
- Trial name
- NCT07657767
- Testing
- Extracorporeal therapy, Extracorporeal elimination of cfDNA using "Nucleocore"
- Where
- Russia
- Volunteers
- 60 people
- Sponsor
- Sergey Savko
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.